Indoco Remedies Ltd 2020 AR2
The report highlights Indoco Remedies Ltd.'s financial and operational performance for the fiscal year 2019-2020, showcasing a return to profitability with revenues reaching INR 1,079 crore. The company successfully addressed regulatory issues at its manufacturing sites, receiving key approvals from the USFDA and UK-MHRA. Indoco launched eight new products in the domestic market, including 'Aloja' for diabetes management, and actively contributed to COVID-19 relief efforts by supplying Paracetamol to the UK and donating to the PM-CARES Fund. Additionally, the company continued its commitment to social responsibility through various community development and healthcare initiatives.
Company: Indoco Remedies Ltd
Sector: Manufacturing
Country: India
Year: 2020
Type: AR2
Pages: 238
Back to company
Indoco Remedies Ltd
Annual Report
The report highlights Indoco Remedies Ltd.'s financial and operational performance for the fiscal year 2019-2020, showcasing a return to profitability with revenues reaching INR 1,079 crore. The company successfully addressed regulatory issues at its manufacturing sites, receiving key approvals from the USFDA and UK-MHRA. Indoco launched eight new products in the domestic market, including 'Aloja' for diabetes management, and actively contributed to COVID-19 relief efforts by supplying Paracetamol to the UK and donating to the PM-CARES Fund. Additionally, the company continued its commitment to social responsibility through various community development and healthcare initiatives.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Apr 1, 2019 - Mar 31, 2020
Fiscal Year
2020
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees